Insider Trading Activity Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) – CFO Sold 538 shares of Stock

ME Staff
-
0

Insider Trading Activity For Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN)

James Engelhart , CFO of Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) reportedly Sold 538 shares of the company’s stock at an average price of 29.6 for a total transaction amount of $15,924.80 SEC Form

Insider Trading History For Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN)

  • On 5/9/2017 Robert Berman, Insider, bought 50 with an average share price of $17.00 per share and the total transaction amounting to $850.00.
  • On 5/9/2017 James Engelhart, CFO, bought 2,500 with an average share price of $17.00 per share and the total transaction amounting to $42,500.00.
  • On 5/9/2017 Albert Cha, Director, bought 470,000 with an average share price of $17.00 per share and the total transaction amounting to $7,990,000.00.
  • On 11/1/2017 Vlad Coric, CEO, sold 150,000 with an average share price of $29.41 per share and the total transaction amounting to $4,411,500.00.
  • On 11/1/2017 Kimberly Gentile, VP, sold 5,000 with an average share price of $29.28 per share and the total transaction amounting to $146,400.00.
  • On 11/1/2017 John Tilton, Insider, sold 30,000 with an average share price of $29.25 per share and the total transaction amounting to $877,500.00.
  • On 11/9/2017 Robert Berman, Insider, sold 27,423 with an average share price of $26.60 per share and the total transaction amounting to $729,451.80.

    • Analyst Ratings History For Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN)

    • On 5/30/2017 Barclays Initiated Coverage of rating Overweight to Overweight with a price target of $30.00
    • On 10/3/2017 Morgan Stanley Reiterated Rating Overweight to Overweight with a price target of $47.00 to $38.00
    • On 10/3/2017 William Blair Reiterated Rating Outperform
    • On 12/11/2017 Piper Jaffray Companies Set Price Target of rating Buy with a price target of $48.00
    • On 2/22/2018 Canaccord Genuity Reiterated Rating Buy to Buy with a price target of $30.00 to $39.00
    • On 2/22/2018 Needham & Company LLC Reiterated Rating Buy

    Recent Trading Activity for Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN)
    Shares of Biohaven Pharmaceutical Holding Co Ltd closed the previous trading session at with shares trading hands.